Suven Life Sciences [SUVEN] vs Hester Biosciences [HESTERBIO] Detailed Stock Comparison
Suven Life Sciences
NSE
Loading...
Hester Biosciences
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Suven Life Sciences wins in 8 metrics, Hester Biosciences wins in 10 metrics, with 0 ties. Hester Biosciences appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Suven Life Sciences | Hester Biosciences | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -30.16 | 48.54 | Suven Life Sciences |
| Price-to-Book Ratio | 44.06 | 5.76 | Hester Biosciences |
| Debt-to-Equity Ratio | 0.00 | 68.46 | Suven Life Sciences |
| PEG Ratio | -0.36 | 0.37 | Suven Life Sciences |
| EV/EBITDA | -25.72 | 29.94 | Suven Life Sciences |
| Profit Margin (TTM) | 84.44% | 11.92% | Suven Life Sciences |
| Operating Margin (TTM) | -2,791.92% | 24.24% | Hester Biosciences |
| EBITDA Margin (TTM) | N/A | 24.24% | N/A |
| Return on Equity | -146.15% | 8.41% | Hester Biosciences |
| Return on Assets (TTM) | -118.91% | 4.21% | Hester Biosciences |
| Free Cash Flow (TTM) | $-1.91B | $439.20M | Hester Biosciences |
| Dividend Yield | N/A | 0.64% | N/A |
| 1-Year Return | 46.42% | -11.94% | Suven Life Sciences |
| Price-to-Sales Ratio (TTM) | 672.60 | 5.74 | Hester Biosciences |
| Enterprise Value | $47.87B | $20.40B | Suven Life Sciences |
| EV/Revenue Ratio | 636.82 | 6.47 | Hester Biosciences |
| Gross Profit Margin (TTM) | 100.00% | 73.29% | Suven Life Sciences |
| Revenue per Share (TTM) | $0 | $361 | Hester Biosciences |
| Earnings per Share (Diluted) | $-8.45 | $43.86 | Hester Biosciences |
| Beta (Stock Volatility) | 0.86 | 0.12 | Hester Biosciences |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Suven Life Sciences vs Hester Biosciences Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Suven Life Sciences | -4.93% | 1.64% | -6.92% | -0.14% | 86.21% | 73.43% |
| Hester Biosciences | -0.89% | 2.87% | 9.56% | 14.21% | 54.66% | -11.43% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Suven Life Sciences | 46.42% | 195.41% | 293.00% | -10.67% | 640.73% | 3,313.08% |
| Hester Biosciences | -11.94% | 1.52% | 20.80% | 260.00% | 358.43% | 358.43% |
News Based Sentiment: Suven Life Sciences vs Hester Biosciences
Suven Life Sciences
News based Sentiment: MIXED
September was a month of contrasts for Suven Life Sciences. While the company faces ongoing financial difficulties, highlighted by continued losses and revenue contraction, the upcoming presentation of clinical trial data for Samelisant offers a potential catalyst for future growth. This creates a mixed investment picture with both significant risks and potential rewards.
Hester Biosciences
News based Sentiment: MIXED
Hester Biosciences reported strong profit growth in the June quarter, but this was offset by concerns about high debt levels and a stock that has underperformed over the past year. The fundamental analysis report highlighting overvaluation adds to the complexity of the investment picture, making September a month of mixed signals.
Performance & Financial Health Analysis: Suven Life Sciences vs Hester Biosciences
| Metric | SUVEN | HESTERBIO |
|---|---|---|
| Market Information | ||
| Market Cap | ₹50.90B | ₹18.15B |
| Market Cap Category | Mid cap | Small cap |
| 10 Day Avg. Volume | 125,748 | 6,827 |
| 90 Day Avg. Volume | 133,614 | 22,113 |
| Last Close | ₹221.85 | ₹2,117.70 |
| 52 Week Range | ₹102.50 - ₹299.99 | ₹1,242.95 - ₹2,786.10 |
| % from 52W High | -26.05% | -23.99% |
| All-Time High | ₹338.50 (Apr 13, 2015) | ₹3,379.00 (Jul 22, 2024) |
| % from All-Time High | -34.46% | -37.33% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.86% | 0.04% |
| Quarterly Earnings Growth | 0.86% | 1.60% |
| Financial Health | ||
| Profit Margin (TTM) | 0.84% | 0.12% |
| Operating Margin (TTM) | -27.92% | 0.24% |
| Return on Equity (TTM) | -1.46% | 0.08% |
| Debt to Equity (MRQ) | 0.00 | 68.46 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹5.04 | ₹369.41 |
| Cash per Share (MRQ) | ₹2.75 | ₹8.49 |
| Operating Cash Flow (TTM) | ₹-1,590,282,000 | ₹554.94M |
| Levered Free Cash Flow (TTM) | ₹-1,607,450,000 | ₹274.88M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.64% |
| Last 12-Month Dividend | ₹0.00 | ₹13.00 |
Valuation & Enterprise Metrics Analysis: Suven Life Sciences vs Hester Biosciences
| Metric | SUVEN | HESTERBIO |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -30.16 | 48.54 |
| Forward P/E | 11.49 | N/A |
| PEG Ratio | -0.36 | 0.37 |
| Price to Sales (TTM) | 672.60 | 5.74 |
| Price to Book (MRQ) | 44.06 | 5.76 |
| Market Capitalization | ||
| Market Capitalization | ₹50.90B | ₹18.15B |
| Enterprise Value | ₹47.87B | ₹20.40B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 636.82 | 6.47 |
| Enterprise to EBITDA | -25.72 | 29.94 |
| Risk & Other Metrics | ||
| Beta | 0.86 | 0.12 |
| Book Value per Share (MRQ) | ₹5.04 | ₹369.41 |
Financial Statements Comparison: Suven Life Sciences vs Hester Biosciences
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SUVEN | HESTERBIO |
|---|---|---|
| Revenue/Sales | ₹18.67M | ₹841.05M |
| Cost of Goods Sold | ₹0 | ₹224.62M |
| Gross Profit | ₹18.67M | ₹616.43M |
| Research & Development | ₹414.88M | N/A |
| Operating Income (EBIT) | ₹-521.17M | ₹186.32M |
| EBITDA | ₹-501.49M | ₹261.79M |
| Pre-Tax Income | ₹-515.17M | ₹201.87M |
| Income Tax | ₹0 | ₹28.91M |
| Net Income (Profit) | ₹-515.17M | ₹172.96M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SUVEN | HESTERBIO |
|---|---|---|
| Cash & Equivalents | ₹150.26M | ₹55.87M |
| Total Current Assets | ₹754.72M | ₹1.95B |
| Total Current Liabilities | ₹234.86M | ₹1.25B |
| Long-Term Debt | N/A | ₹1.39B |
| Total Shareholders Equity | ₹1.10B | ₹3.27B |
| Retained Earnings | ₹-6.01B | ₹2.37B |
| Property, Plant & Equipment | ₹756.69M | ₹59.22M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SUVEN | HESTERBIO |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SUVEN | HESTERBIO |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 125,748 | 6,827 |
| Average Daily Volume (90 Day) | 133,614 | 22,113 |
| Shares Outstanding | 218.07M | 8.51M |
| Float Shares | 61.27M | 2.68M |
| % Held by Insiders | 0.69% | 0.69% |
| % Held by Institutions | 0.02% | 0.00% |
Dividend Analysis & Yield Comparison: Suven Life Sciences vs Hester Biosciences
| Metric | SUVEN | HESTERBIO |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | ₹13.00 |
| Last 12-Month Dividend Yield | N/A | 0.64% |
| 3-Year Avg Annual Dividend | ₹0.00 | ₹10.33 |
| 3-Year Avg Dividend Yield | N/A | 0.37% |
| 3-Year Total Dividends | ₹0.00 | ₹31.00 |
| Ex-Dividend Date | N/A | Aug 06, 2025 |